Ligand Pharmaceuticals (LGND) Financials: History & Chart

Ligand Pharmaceuticals Incorporated(LGND)

Biotechnology · Jupiter, FL

$297.31-9.46 (-3.08%)

Delayed quote: Oct 6, 2026, 2:25 PM EDT

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.

Jupiter, FL

47 employees

www.ligand.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Todd C. Davis

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	290.54M	63.69M	51.72M	59.67M	115.46M	47.63M	45.33M	42.81M	51.81M
Cost of Goods Sold	4.12M	3.21M	2.08M	-25.99M	24.82M	2.91M	4.85M	2.84M	12.49M
Gross Profit	286.42M	60.48M	49.65M	85.65M	90.64M	44.72M	40.48M	39.98M	39.32M
Gross Profit Margin	98.6%	95.0%	96.0%	143.6%	78.5%	93.9%	89.3%	93.4%	75.9%
Total Operating Expenses	185.49M	51.89M	32.28M	65.61M	35.71M	36.28M	76.70M	49.61M	36.17M
Research & Development	41.35M	14.67M	2.15M	3.51M	21.02M	6.57M	50.09M	4.42M	5.67M
Selling, General & Administrative	103.43M	29.12M	20.84M	25.03M	28.45M	20.18M	18.80M	25.61M	24.48M
Operating Income (EBIT)	100.93M	8.59M	17.37M	20.04M	54.93M	8.44M	-36.22M	-9.64M	3.14M
Operating Margin	34.7%	13.5%	33.6%	33.6%	47.6%	17.7%	-79.9%	-22.5%	6.1%
Income Before Tax (EBT)	237.96M	64.30M	-24.26M	56.78M	141.14M	11.22M	-50.18M	-39.20M	-6.34M
Interest Income	24.22M	7.30M	6.66M	6.39M	3.87M	1.62M	1.77M	1.93M	1.35M
Interest Expense	6.19M	1.75M	1.75M	1.78M	910K	1.15M	867K	883K	741K
Other Income/Expense	137.03M	55.71M	-41.63M	36.74M	86.21M	2.78M	-13.96M	-29.56M	-9.48M
Net Income	197.22M	48.51M	-13.35M	44.78M	117.27M	4.85M	-42.45M	-31.09M	-7.17M
Income Tax Expense	40.74M	15.80M	-10.91M	12.00M	23.86M	6.38M	-7.73M	-8.11M	833K
Net Profit Margin	67.9%	76.2%	-25.8%	75.1%	101.6%	10.2%	-93.6%	-72.6%	-13.8%
EBITDA	134.96M	16.69M	25.58M	29.66M	63.03M	16.97M	-27.45M	-1.01M	12.14M
EBITDA Margin	46.5%	26.2%	49.5%	49.7%	54.6%	35.6%	-60.5%	-2.4%	23.4%
Depreciation & Amortization	34.03M	8.10M	8.22M	9.62M	8.10M	8.52M	8.77M	8.63M	8.99M
EPS Basic	10.01	2.42	-0.67	2.27	5.99	0.25	-2.21	-1.64	-0.39
EPS Diluted	9.35	2.22	-0.67	2.12	5.68	0.24	-2.21	-1.64	-0.39
Weighted Average Basic Shares	20.06M	20.06M	19.88M	19.73M	19.37M	19.33M	19.19M	18.97M	18.42M
Weighted Average Diluted Shares	21.84M	21.84M	19.88M	21.14M	20.17M	19.93M	19.19M	18.97M	18.42M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	268.09M	167.13M	131.31M	196.25M	241.54M	163.56M	120.28M	251.45M
Cost of Goods Sold	6.59M	11.07M	35.05M	52.83M	62.18M	30.42M	11.35M	6.34M
Gross Profit	261.50M	156.06M	96.27M	143.42M	179.37M	133.14M	108.94M	245.12M
Gross Profit Margin	97.5%	93.4%	73.3%	73.1%	74.3%	81.4%	90.6%	97.5%
Total Operating Expenses	214.30M	178.66M	84.32M	140.38M	75.52M	95.64M	-698.14M	81.39M
Research & Development	81.18M	21.43M	24.54M	36.08M	32.10M	40.50M	55.91M	27.86M
Selling, General & Administrative	92.45M	78.65M	52.79M	70.06M	46.79M	60.01M	41.88M	37.73M
Operating Income (EBIT)	47.20M	-22.61M	11.94M	3.04M	103.85M	37.50M	807.08M	163.73M
Operating Margin	17.6%	-13.5%	9.1%	1.5%	43.0%	22.9%	671.0%	65.1%
Income Before Tax (EBT)	158.96M	2.52M	63.66M	36.01M	72.20M	1.29M	796.64M	173.33M
Interest Income	13.66M	8.05M	7.71M	2.05M	886K	8.08M	28.43M	14.00M
Interest Expense	4.71M	3.04M	656K	1.80M	19.62M	27.41M	35.74M	48.28M
Other Income/Expense	111.76M	25.12M	51.72M	32.97M	-31.65M	-36.21M	-10.44M	9.60M
Net Income	124.45M	-4.03M	52.15M	-33.36M	57.14M	-2.98M	629.30M	143.32M
Income Tax Expense	34.51M	6.55M	9.84M	41.23M	-4.15M	-5.31M	167.34M	30.01M
Net Profit Margin	46.4%	-2.4%	39.7%	-17.0%	23.7%	-1.8%	523.2%	57.0%
EBITDA	80.97M	12.63M	48.46M	46.43M	154.80M	65.47M	850.81M	180.42M
EBITDA Margin	30.2%	7.6%	36.9%	23.7%	64.1%	40.0%	707.3%	71.8%
Depreciation & Amortization	33.77M	35.24M	36.52M	43.39M	50.95M	27.97M	43.73M	16.69M
EPS Basic	6.44	-0.22	3.02	-1.98	3.46	-0.18	33.13	5.96
EPS Diluted	6.13	-0.22	2.94	-1.98	3.34	-0.18	31.85	5.96
Weighted Average Basic Shares	19.34M	18.29M	17.30M	16.87M	16.63M	16.18M	19.00M	24.05M
Weighted Average Diluted Shares	20.29M	18.29M	17.76M	16.87M	17.25M	16.18M	19.76M	24.07M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.